Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neisseria meningitidis group w-135 capsular oligosaccharide diphtheria crm197 protein conjugate antigen
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Neisseria meningitidis group w-135 capsular oligosaccharide diphtheria crm197 protein conjugate antigen is a component of certain quadrivalent and pentavalent meningococcal vaccines. It consists of the purified capsular polysaccharide (oligosaccharide) from Neisseria meningitidis serogroup W-135, which is chemically linked (conjugated) to the non-toxic mutant CRM197 protein derived from Corynebacterium diphtheriae. This conjugation enhances immunogenicity by inducing a T-cell dependent immune response, resulting in improved antibody production and immunological memory compared to unconjugated polysaccharides. The primary indication is for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup W[1][4][6]. This antigen is included as one of four components in quadrivalent vaccines such as Menveo, which also target serogroups A, C, and Y.
- Other names
- Neisseria meningitidis group w-135 capsular oligosaccharide diphtheria crm197 protein conjugate antigen
02
Targets
MenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)
Beyond the preview
Go deeper on Neisseria meningitidis group w-135 capsular oligosaccharide diphtheria crm197 protein conjugate antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neisseria meningitidis group w-135 capsular oligosaccharide diphtheria crm197 protein conjugate antigen.